Osteoarthritis: 500 million patients. $560 billion a year spent. No drug that stops it.

Cytonics is developing a potential disease-modifying therapy that targets osteoarthritis at its root cause, not just the pain.

  1. Cleared Phase 1 human trials.
  2. Advancing toward Phase 1b/2a with a version engineered to be 200% more potent.
  3. Backed by research from Stanford University and Scripps.
  4. Projected 25X valuation growth at Phase 1b/2a completion
Reserve Shares

Looking to finalize your investment? Click below

Sign in
3D knee joint model receiving a therapeutic injection into red inflamed cartilage with dark blue background

Reserve Shares

Join the waitlist by reserving shares.

Invest Now
10,000+
Patients treated with first-gen therapy
$38.5M+
Total Capital Raised
$1.8M
in National Institutes of Health grants awarded
26
Patents issued worldwide
"These statements reflect management’s current views based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results. Please see Data Room for additional detail regarding the assumptions underlying these projections."
Translucent 3D visualization of a human knee joint glowing blue, highlighting bone and cartilage structure
Market Opportunity

Osteoarthritis Therapeutics Is a $560B+ Market With No Real Cure

500M+ people worldwide live with osteoarthritis. Every current treatment only masks the pain while the disease quietly progresses toward costly, invasive joint replacements. Big Pharma spent $1B+ chasing a cure and came up short, because they targeted a single enzyme with an oral drug rather than addressing the full complexity of the disease.

Bar chart of Cytonics risk-adjusted valuation from $65M pre-clinical to $27.7B after FDA approval across six stages
Problem
Green DNA double helix icon representing Cytonics biotechnology and molecular science

But No Drug Works

That means 500M+ global patients are getting short-term fixes like anti-inflammatories and corticosteroid shots. These may dull pain, but the disease still progresses toward costly, painful, and invasive joint replacements. We believe that this is unacceptable.

Big Pharma has spent $1B+ chasing a true “disease-modifying” therapy capable of halting OA in its tracks and repairing cartilage tissue, but their strategy has failed to appreciate the multi-faceted nature of the disease and they’ve consistently come up short.

Problem
Green icon of a microscope and test tube representing Cytonics scientific research

Here’s Why Big Pharma is Failing

Every drug fails for the same reason: they go after just one target. But OA is complex, caused by a team of cartilage-destroying enzymes called “proteases”. If you don’t stop them all, the damage continues and the disease spirals out of control. Further compounding their shortsighted approach, they’ve attempted to deliver drugs orally, not directly into the joint.

A2M protein molecule in cyan capturing red inflammatory particles, visualizing Cytonics' molecular approach to OA treatment
SOLUTION

Cytonics took a different approach: CYT-108

Cytonics is developing the first potential disease-modifying therapy for osteoarthritis. CYT-108 is its leading drug candidate under investigation in FDA human clinical trials. It is designed to attack osteoarthritis at its root cause, delivering potent protease inhibition and cartilage repair directly into the joint.

Designed to attack osteoarthritis at its root cause, delivering potent protease inhibition and cartilage repair directly into the joint.

Protease inhibitor with potent inhibitory activity against
the proteases that are upregulated in OA

Targets OA at its root cause to protect cartilage damage and the joint membrane

Scripps Research logo with gold infinity symbol and black textSRI International (Stanford Research Institute) logo with globe emblem in dark blue

Ind. research corroborates Cytonics’ hypothesis that A2M can regenerate cartilage

Scripps Research logo with gold infinity symbol and black textSRI International (Stanford Research Institute) logo with globe emblem in dark blue

Highly concentrated for targeted delivery directly into joint space

Scripps Research logo with gold infinity symbol and black textSRI International (Stanford Research Institute) logo with globe emblem in dark blue

Preclinical studies demonstrate significant reduction in the progression of OA

Scripps Research logo with gold infinity symbol and black textSRI International (Stanford Research Institute) logo with globe emblem in dark blue

Capable of manufacturing at scale and global distribution as a shelf-stable compound

Scripps Research logo with gold infinity symbol and black textSRI International (Stanford Research Institute) logo with globe emblem in dark blue
Reserve Shares

So, that’s exactly what we did.

In 2018, we engineered a variant of the natural A2M gene sequence to contain small mutations designed to improve its ability to inhibit the most deleterious proteases involved in OA. Our lead drug candidate, “CYT-108” has been proven to be over 200% more potent than the natural A2M when delivered directly into the joint via intra-articular injection.

Digital illustration of inflamed knee joint showing muscles, bones, and molecular structures with a glowing pain point

This highly potent and concentrated CYT-108 produces a durable anti-inflammatory and cartilage repair response.

After 7 years and over $10M spent in preclinical research, we recently concluded our first-in-human Phase 1 clinical trial, clearly demonstrating the safety of 25mg CYT-108 injected directly into arthritic knees.

Now, we are gearing up for Phase 1b/2a clinical studies to establish efficacy in a statistically significant and clinically meaningful way.

A2M protein trapping inflammatory particles, illustrating Cytonics' molecular therapy for osteoarthritis

The result?

After 7 years and over $10M spent in preclinical research, we recently concluded our first-in-human Phase 1 clinical trial, clearly demonstrating the safety of 25mg CYT-108 injected directly into arthritic knees.

Now, we are gearing up for Phase 1b/2a clinical studies to establish efficacy in a statistically significant and clinically meaningful way.
Medical professional administering an ultrasound-guided injection to a patient's shoulder in a clinical setting

How CYT-108 Works

CYT-108 is a genetically engineered “super A2M” protein that is >200% more potent than the naturally-occurring A2M protein

A2M is a naturally-occurring protease inhibitor that protects against cartilage degradation, but levels are too low in joints to be an effective treatment.

CYT-108 is delivered in massive, supraphysiological concentrations (17x natural A2M levels in the joint) for extremely potent inhibition of proteases and stimulation of cartilage-secreting chondrocytes.

1

3D knee joint model receiving a therapeutic injection into red inflamed cartilage with dark blue background
Delivered directly into the joint, where the damage is actually happening

2

A2M protein trapping inflammatory particles, illustrating Cytonics' molecular therapy for osteoarthritis
Blocks the full cascade of enzymes destroying cartilage, not just one

3

3D close-up of knee joint showing therapeutic particles dispersing through translucent cartilage between bone surfaces
Reduces pain and rebuilds cartilage at the source
Decorative horizontal dividerDecorative horizontal divider

A2M: Leveraging Natures Beautiful Design

At the core of our technology is Alpha-2-macroglobulin (A2M) - a naturally occurring protein that acts as the body’s molecular defense system. It is found in the blood stream and plays a role in blood clotting through a mechanism called protease inhibition. Cartilage breakdown in arthritis is also caused by these destructive proteases. Cytonics hypothesized that A2M’s mechanism of action could be leveraged to inhibit the multitude of protease enzymes that drive cartilage breakdown in arthritic joints.

A2M is one of the most well-studied proteins in human biology. Its structure was crystallized in 2012, and more than 90,000 peer-reviewed studies support its role as abroad-spectrum protease inhibitor. Its two “bait regions” function like a molecular Venus Flytrap, binding and deactivating these destructive enzymes. A2M is such a potent protease destroyer that it has been dubbed the Physiological Guardian because of its ability to protect many different tissue types throughout the body.

“So, if the human body is already full of A2M in the bloodstream, then why doesn’t it just naturally protect joints from arthritic decay?”

The issue is concentration and localization. Specifically, natural A2M levels inside the joint are too low to provide therapeutic benefit.

Cytonics’ approach is simple: Leverage the therapeutic power of A2M by delivering high concentrations of this miraculous protein directly into arthritic joints to halt cartilage damage, reduce joint membrane inflammation, and stimulate cartilage regrowth.

APIC™: Harnessing the Power of A2M

The First Generation Technology

10,000+

Patients Treated

300+

Physicians Trained

Problem

200%

More Potent (CYT-108)

“Regenerative orthopedics” has been dominated by stem cells, PRP, and other autologous treatments - many unproven, unregulated, and not reimbursed by insurance payers. This is where Cytonics broke away from the pack.

Our next-generation therapy, APIC™ (Autologous Protease Inhibitor Concentrate), put Alpha-2-Macroglobulin (A2M) on the clinical map and into the offices of orthopedists nationwide. Using a proprietary filtration system, APIC™ isolates and concentrates A2M from a patient’s blood and re-injects it into the joint to inhibit cartilage breakdown and promote regeneration at the molecular level.

But as effective as APIC™ is, it has limitations: variable A2M levels between patients, multi-hour processing, and equipment requirements that constrain scalability.

These constraints inspired the next evolution in our platform: an engineered, highly potent version of A2M designed for more potent treatment on a global scale for wide-spread accessibility: We called this miraculous therapy CYT-108.

From APIC™ to CYT-108: The Next Generation of A2M Therapies

CYT-108 was designed to address APIC™’s limitations. Using recombinant genetic engineering, we created a “super A2M” variant that is 200% more potent than the natural A2M and can be produced on a global scale in consistent, supraphysiological concentrations and dosed precisely in every patient and every joint.

This is a true biopharmaceutical approach to solving osteoarthritis on a global scale.

3D surface model of the A2M protein with translucent cyan exterior and magenta internal regions on transparent background
Natural A2M: APIC purified from patient blood
Detailed ribbon-diagram of the CYT-108 protein structure in cyan, magenta, and yellow, with trapped red inflammatory molecules
CYT-108: genetically-engineered (recombinant) A2M
Invest Now
Source
Efficacy
Scalability
Insurance Coverage
APIC™
Patient's own blood
Patient-to-patient variability
Limited by blood processing
Uncertain
CYT-108
Genetically-engineered (recombinant A2M)
Precisely dosed, 200% more potent & optimized against MMP- 13 and ADAMTS-5
Laboratory production
High potential

See the Science Behind the Breakthrough

Roadmap

2026 Is a Critical Year for Cytonics

Today's financing values Cytonics at $160M, at the Phase 1 stage. With our successful Phase 1 clinical trial in 2025 behind us, preparations underway for our next clinical study and a growing pipeline beyond osteoarthritis, 2026 is set to be a defining year for Cytonics.

2026–2027

  • In progressDose optimization study Q3 2026
  • Type C Meeting with FDA Q4 2026
  • File Investigational New Drug application with FDA Q1 2027
  • Phase 1b/2a First-Patient-In Q2 2027
  • Expand A2M pipeline into oncology

2028–2029

  • Phase 1b/2a Last Patient In Q4 2028
  • Last Patient Last Visit Q1 2029
  • Clinical Study Report for FDA review Q3 2029
  • Preclinical oncology experiments

2030+

  • IPO, acquisition, or strategic partnership
  • Phase 3 pivotal studies
  • Biologic License Application (BLA) drug approval
  • Continue expansion of A2M pipeline into oncology
‍Source: Cytonics Investor Deck, Page 17.
"These statements reflect management’s current views based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results. Please see Data Room for additional detail regarding the assumptions underlying these projections."
Two Gracie Jiu-Jitsu athletes in branded gis demonstrating a grappling technique on dark training mats

“As a patient who has personally benefited from the Cytonics A2M therapy, I asked if I could be a partner to help spread the word. I have seen far too many times people get sidelined from their passions because their bodies don't respond and their bodies don't work and they exist in chronic pain. So if we can help reduce or eliminate that pain and delay the onset of chronic osteoarthritis, I'm all for it, sign me up."

Rener Gracie
Third-generation Brazilian Jiu-jitsu Master
Co-founder of Gracie University
Strategic partner/investor in Cytonics
"The following statement reflects the personal opinion of a current investor in Cytonics and is provided for informational purposes only. The testimonials presented are the opinions of the individuals providing them, may not represent the experience of all investors, and are not a guarantee of future performance or success. The individual was not compensated for this testimonial and has a financial interest in Cytonics as an investor. This testimonial does not constitute investment advice, a recommendation, or a guarantee of any investment outcome."
Partnerships

Strategically Partnered with Rener & Eve Gracie

A third-generation Brazilian Jiu-Jitsu master and former WWE champion, Rener and Eve Gracie’s investment in Cytonics carries real weight. As two of the world’s most respected figures in athletics, injury prevention, and health advocacy, they bring credibility, visibility, and real-world expertise.

Two Gracie Jiu-Jitsu athletes sitting on training mats in branded rash guards, representing Cytonics partnership

Health & Performance Advocacy:

As co-founders of Gracie University, with a global network of 2M+ athletes, they’re uniquely positioned to champion our mission.

Real-World Alignment:

Decades of firsthand experience managing joint strain and recovery brings an authentic, athlete-centered voice to our mission to heal rather than mask pain.

Brand Expansion & Awareness:

Vastly expand our reach into global health by accelerating awareness and long-term growth into international markets.
Updates

Stay connected with the latest developments at Cytonics

Jun 29, 2026

Phase 1 Clinical Study Report for CYT-108, Advancing Program Toward Next Phase of Development

Banner with title "Optimizing CYT-108 for the Next Phase of Development"
Jun 22, 2026

Clinical Development & Regulatory Strategy Update

Jun 15, 2026

Why Current Osteoarthritis Therapies Fall Short

Jun 08, 2026

CYT-108 Beyond Arthritis

Jun 01, 2026

Duke ARPA-H (Tissue Regeneration Story)

May 26, 2026

CEO Profile

Phase 1 Study report finalized banner image
May 11, 2026

Phase 1 Study Report Finalized.

May 04, 2026

Founder Profile.

April 27, 2026

Intro Medical Advisory Board.

April 20, 2026

New Canadian Patent.

April 13, 2026

Clinical Development Is Not Hope. It’s Design.

April 10, 2026

Phase 1 Study Report Drafted.

March 17, 2026

We are scaling the biology

March 10, 2026

We’re Live. Again. And We’re Not Slowing Down.

Team

Led by Seasoned Scientists, Physicians, and Industry Outsiders

Our leadership combines world-class scientific expertise, decades of clinical experience, and a proven track record in biotech R&D with the first-principles thinking of biotech neophytes (our Founder and CEO). Our Board of Directors and Medical Advisory Board have dominated the last decade of osteoarthritis research (a combined 80 osteoarthritis clinical trials), developed FDA-approved biologics at major pharma companies, and raised millions in combined capital. This unique combination of traditional biotech experience with avant garde thinking of industry outsiders gives us a strategic advantage as we tackle a problem that the Big Pharma giants have failed to solve.

Gaetano Scuderi, Cytonics Founder, smiling in a white lab coat with a patterned tie (black and white)
Gaetano Scuderi
MD, Founder & Chairman of the Board
Joey Bose, Cytonics CEO, smiling warmly with a beard in a suit jacket and open-collar shirt
Joey Bose
CEO & President
Alan Lewis, Cytonics team member, smiling in a dark suit and patterned tie with wire-frame glasses
Alan Liss
PhD, Head of Quality & Manufacturing
Michael Hartwich, Cytonics team member, smiling broadly with curly hair in a dark t-shirt
Michael Hartwich
Head of Creative Development & Digital Advertising
Alex, Cytonics team member, with shoulder-length hair and rectangular glasses in a dark top
Alex Barton
Head of AI Integration

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

March

Title

update...

phrase...